Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28
Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28
What changed
Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28
Why it matters
Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28 — impact context not separately stored; see What changed.
← Dashboard
Aug 10, 2026 11:29 AM ET